About Plabeltech
Plabeltech is a Healthcare company based in Bhopal (India) founded in 2018 by Vishal Rai. It operates as a provider of products and services for protein engineering. Its Indian entity Plabeltech Private Limited reported revenue of ₹10.1 Lakh. Plabeltech offers products and services including MS Sensitivity Booster-PS1, MS Sensitivity Booster-PD1, MS Sensitivity Booster-BC1, and Gly-Tag Purification Resin. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Similar companies include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group and 5 more; 8 of its 10 listed similar companies have raised funding.
Company details
Plabeltech is the provider of products and services for protein engineering. The company delivers labeling of proteins and antibodies with the probe of interest. They also developed the in-house kit for multifold enhancement in the sensitivity of peptide detection (MS), peptide mapping (MS), and their fragments (MS-MS). They also provide product for purification and isolation of proteins with Gly residue at the N-terminus.
- Headquarters Bhopal, India
- Founders Vishal Rai
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website plabeltech.com
- Social LinkedIn X Facebook
- Legal Name Plabeltech Private Limited
- Date of Incorporation 08 Mar, 2018
- Jurisdiction Bhopal, Madhya Pradesh, India
- Annual Revenue₹10.1 Lakh
FY 2025 · +324% YoY
- Net Profit₹5.9 Lakh
FY 2025 · 59% margin
- EBITDA₹8.6 Lakh
FY 2025 · 86% margin
Associated legal entities of Plabeltech
Plabeltech operates through Plabeltech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Plabeltech Private Limited CIN U24299MP2018PTC045210 | Active | 08 Mar 2018 | Bhopal, Madhya Pradesh | ₹0.1 Cr | – | 2 | View details |
Products & Services of Plabeltech
Plabeltech offers a comprehensive portfolio of products and services, including MS Sensitivity Booster-PS1, MS Sensitivity Booster-PD1, MS Sensitivity Booster-BC1, and Gly-Tag Purification Resin.
Enhances peptide detection in mass spectrometry analysis.
Boosts protein detection for accurate spectrometry results.
Improves biomolecule sensitivity in mass spectrometry.
Facilitates efficient purification of tagged proteins.
Board of directors of Plabeltech Private Limited (Plabeltech)
Plabeltech Private Limited is the primary company behind Plabeltech. The board of Plabeltech Private Limited currently have 2 directors; the longest-serving is Vishal Rai, appointed in 2018.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vishal Rai DIN 08055709 | Director | 08 Mar 2018 | 8 yrs 7 mo | Plabeltech Private Limited |
| Vikas DIN 07779228 | Director | 08 Mar 2018 | 8 yrs 7 mo | Plabeltech Private Limited |
People of Plabeltech
1 people are tracked at Plabeltech (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder | Leadership |
Complete people profiles for Plabeltech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Plabeltech
Figures of Plabeltech Private Limited, the primary company behind Plabeltech, for FY 2025. Revenue was ₹10.1 Lakh (+324% year on year). Net profit was ₹5.9 Lakh (59% margin). EBITDA was ₹8.6 Lakh (86% margin). Revenue has grown at a compounded annual rate of -17% over three years and +7% over five years.
- ₹10.1 LakhRevenue · FY 2025 · +324% YoY
- ₹5.9 LakhNet profit · 59% margin
- ₹8.6 LakhEBITDA · 86% margin
- ₹1.1 LakhPaid-up capital
- -17%Revenue CAGR, 3 years
- +7%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Plabeltech Private Limited are on its company page.
Detailed financial statements for Plabeltech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Plabeltech
Plabeltech has 10 listed similar companies in our database, 8 of them funded. They include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed similar companies of Plabeltech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Plabeltech (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Plabeltech
Plabeltech was founded in 2018.
Plabeltech is headquartered in Bhopal, India. It is registered at Bhopal, Madhya Pradesh, India.
The primary company behind Plabeltech, Plabeltech Private Limited, reported revenue of ₹10.1 Lakh for FY 2025, up 324% year on year.
Plabeltech is the provider of products and services for protein engineering. The company delivers labeling of proteins and antibodies with the probe of interest. They also developed the in-house kit for multifold enhancement in the sensitivity of peptide detection (MS), peptide mapping (MS), and their fragments (MS-MS). They also provide product for purification and isolation of proteins with Gly residue at the N-terminus.
Plabeltech's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Plabeltech offers MS Sensitivity Booster-PS1, MS Sensitivity Booster-PD1, MS Sensitivity Booster-BC1, and Gly-Tag Purification Resin.
Plabeltech operates through Plabeltech Private Limited.
The legal entities of Plabeltech currently have 2 directors, including Vishal Rai, Vikas.